Biliary Tract Malignancy

September 2011

Pancreatobiliary tumors such as cholangiocarcinoma (bile duct cancer) or pancreatic cancer often present as biliary tract obstruction or strictures. Bile duct or hepatobiliary brushing specimens obtained during endoscopic retrograde cholangiopancreatography (ERCP) are used to assess affected patients for possible malignancy using cytologic and molecular techniques. We have developed a statistical model that incorporates routine cytology and FISH test results with clinical factors to predict risk of malignancy in an individual patient.

Presenters:

• Gregory Gores, MD, chair of the Division of Gastroenterology and Hepatology and Professor of Medicine and Physiology in the College of Medicine at Mayo Clinic
• Kevin Halling, MD, PhD, vice chair for research and development for the Department of Laboratory Medicine and Pathology and consultant in the Division of Laboratory Genetics at Mayo Clinic in Rochester, Minnesota

Print Options

• Before viewing, print the Notes Pages.
• After viewing, obtain a Record of Viewing.

Related Tests

• #84357 Biliary Tract Malignancy, Cytology & Molecular Testing
• #19701 Biliary Tract Malignancy, FISH Only

Forward to a Colleague

Share this presentation with:

• Gastroenterologists/Hepatologists
• Surgical and Cytopathologists
• Interventional Radiologists
• Oncologists
• Internal Medicine Physicians

If you have general questions about a Clinical Insight presentation, e-mail